Ashutosh Chilkoti
About Ashutosh Chilkoti
Ashutosh Chilkoti is the Chairman and Chair of the Biomedical Engineering Department at Duke University, known for his pioneering work in recombinant proteins.
Chairman of Biomedical Engineering at Duke University
Ashutosh Chilkoti is the Chairman of the Biomedical Engineering Department at Duke University. In his leadership role, he oversees the academic and research activities of the department, contributing to the advancement of biomedical engineering education and innovation. His work at Duke University enables him to mentor students and collaborate with other experts in the field, fostering a vibrant academic community.
Pioneered Academic and Industrial Application of Recombinant Proteins
Ashutosh Chilkoti is recognized for pioneering the academic and industrial application of recombinant proteins. His ground-breaking research has paved the way for new methodologies and technologies within the biomedical sector. By integrating recombinant protein research with practical applications, he has significantly influenced both academic pursuits and commercial developments in biotechnology.
Publications and Patents in Recombinant Proteins
Ashutosh Chilkoti has an extensive portfolio of work, including over 400 publications and 70 patents focused on recombinant proteins. His scholarly articles contribute to advancing knowledge and understanding within the scientific community. The patents highlight his innovative contributions to the field, including novel approaches and technologies that have practical applications in medicine and biotechnology.
Founder of Startup Companies
Ashutosh Chilkoti has founded multiple startup companies, leveraging his research and expertise to foster innovation in the biotechnology industry. Among them, PhaseBio Pharmaceuticals stands out as a publicly traded company. PhaseBio has successfully advanced drug delivery technologies into Phase 2 clinical trials, demonstrating the practical impact of Chilkoti's entrepreneurial efforts in translating academic research into commercial success.